Allos Therapeutics

Earnings Report: Allos Therapeutics Remains Up 22%, Earnings Release Follows Positive Trial Report

Allos Therapeutics (ALTH) reports a second quarter loss of 19 cents, a penny better than the Thomson Reuters mean analyst estimate for a loss of $0.20. Net product sales were $7.9 million for the second quarter of 2010, which represents the $9 million of gross product sales net of $1.1 million of gross to net sales adjustments. The company earlier announced topline results from the companys... ...